Not medical advice. Talk to your provider before using any peptide. Full disclaimer
GHRP-6
Beginner tier: 100 mcg, daily · community consensus
Also known as: GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone peaks in under 20 minutes. GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic ghrelin mimetic that triggers a strong pituitary GH pulse. Human pharmacokinetic data from Cabrales and colleagues [1] confirmed a rapid distribution half-life of 7.6 minutes in nine healthy men. The catch: it also floods you with hunger. Ghrelin receptor agonism makes appetite surge roughly 20 minutes after injection, which is either a gift or a problem depending on your goals. Bodybuilders and hard gainers stack it with CJC-1295 No DAC for amplified pulses during bulking phases.
What Is GHRP-6?
GHRP-6 (Growth Hormone Releasing Peptide-6, CAS 87616-84-0) is a synthetic hexapeptide that binds the growth hormone secretagogue receptor (GHS-R1a) at the pituitary gland. In swine, its peak GH level was similar to ipamorelin's [10], but the trade-offs are real. Cabrales and colleagues characterized its pharmacokinetics in nine healthy male volunteers using IV administration [1], landing on a distribution half-life of 7.6 minutes and an elimination half-life around 2.5 hours. The commonly cited plasma half-life sits at roughly 20 minutes.
What separates GHRP-6 from cleaner secretagogues like ipamorelin is its ghrelin mimicry. GHS-R1a is the ghrelin receptor, so agonism there doesn't just release GH. It also triggers orexigenic signaling that makes appetite spike within 20 minutes of injection. Cortisol and prolactin rise as well. In Bowers' study of 18 healthy men, both roughly doubled at 1 mcg/kg IV but not at lower doses [7]. Taken orally or intranasally, GHRP-6 left cortisol unchanged [2].
Community adoption across thousands of users on r/Peptides and bodybuilding forums has been consistent for over a decade. The top protocol pairs 100 mcg GHRP-6 with 100 mcg CJC-1295 No DAC (Mod GRF 1-29), injected two to three times daily on an empty stomach. Users report improved sleep, faster recovery, and lean mass accrual over 8 to 12 week cycles. No randomized controlled trials exist for body composition outcomes in healthy adults; the evidence base for performance use relies on GH-stimulation data extrapolated through community experience.
How GHRP-6 Works
GHRP-6 binds the growth hormone secretagogue receptor type 1a (GHS-R1a) on pituitary somatotrophs. Lei and colleagues [3] showed that this binding stimulates phosphatidylinositol turnover, a calcium-dependent intracellular cascade that triggers growth hormone release from secretory granules. The result is a rapid, pulsatile GH spike detectable in serum within 15 to 30 minutes of subcutaneous injection.
GHS-R1a is the endogenous ghrelin receptor. GHRP-6 mimics ghrelin's action at this site, which means it doesn't just release GH. It also activates orexigenic (appetite-stimulating) pathways through the hypothalamus. This dual action separates GHRP-6 from more selective GHRPs like ipamorelin, which produce GH pulses without the hunger surge.
Beyond GH release, Berlanga-Acosta and colleagues described a separate receptor pathway through CD36. Their 2017 review [4] and subsequent 2024 cardioprotection study (PMC11169835) demonstrated cytoprotective effects in animal models, including wound healing acceleration [5] and cardiac protection against doxorubicin toxicity. These CD36-mediated effects operate independently of GH signaling.
GHRP-6 also produces mild ACTH and cortisol elevation, along with a small prolactin increase. Bowers' group saw prolactin and cortisol about double at 1 mcg/kg IV [7]. Frieboes and colleagues found ACTH and cortisol rose after IV doses at night [6]; after oral or intranasal doses, cortisol stayed unchanged [2].
GHRP-6 Benefits
- GHRP-6 benefits center on powerful GH secretion and appetite-driven mass gain.
- - Produces a strong GH pulse. At 1 mcg/kg IV, peak GH reached about 69 µg/L in healthy men [7]. Community reports describe the GH and hunger effects within 15 to 30 minutes of injection. - Appetite stimulation through ghrelin receptor agonism hits within 20 minutes post-dose; hard gainers and bulking athletes treat this as a primary feature rather than a side effect. - Stacking with CJC-1295 No DAC (Mod GRF 1-29) produces complementary GH amplification because the two peptides act on different receptor pathways (GHS-R1a and GHRH receptor respectively). - Community users consistently report deeper sleep and faster recovery between training sessions, particularly with pre-bed dosing. - Cytoprotective properties shown in preclinical models, including wound healing acceleration [5] and cardioprotection via CD36 receptor binding [4], though these findings have not been confirmed in human performance contexts.
GHRP-6: Science vs Community Consensus
Well-established GH secretagogue via GHS-R1a agonism; also binds CD36 producing cytoprotective effects independent of GH release.
Read the evidence (key study, limitations)
Clinical GH-stimulation data is solid (1990s–2000s human trials). Performance/body-composition RCTs do not exist. Cytoprotective evidence is primarily preclinical.
Cabrales et al. Eur J Pharm Sci 2013 (PMID 23099431): IV pharmacokinetics in nine healthy men; Bowers et al. foundational GH-stimulation studies 1980s–1990s; Berlanga et al. Frontiers Pharmacology 2024 (PMC11169835): cardioprotection against doxorubicin in rats
No dose-ranging RCTs for performance/body-composition outcomes in healthy adults. Cytoprotection data is animal models only. Plasma levels fall fast after IV dosing (distribution half-life 7.6 min, elimination 2.5 h, PMID 23099431). Regulatory status (503B Category 2, 503A Category 3) limits clinical access.
Widely used for mass-gaining protocols due to intense appetite stimulation and strong GH pulse.
Read the reports (what users report 5, common issues 6)
Often stacked with CJC-1295 No DAC as a GHRH/GHRP pair. Considered the best GHRP for bulking; appetite side effect is treated as a benefit.
- Intense hunger increase (useful for hard gainers / bulking)
- Noticeable GH pulse within 15–30 min of injection
- Improved sleep quality and depth with evening dosing
- Faster recovery between sessions
- Lean mass accrual over 8–12 week cycles
- Hunger is difficult to manage on cuts: often limits use to bulking phases
- Requires 3 injections/day for full effect: high injection burden
- Water retention at higher doses
- Tingling, dizziness, flushing post-injection (GH pulse effect)
- Mild cortisol and prolactin elevation compared to ipamorelin
- Receptor desensitization if cycled continuously beyond 8–12 weeks
Science confirms GHS-R1a agonism and acute GH release in humans. Community protocols extrapolate from mechanism to performance outcomes without RCT support. Appetite stimulation (ghrelin mimicry) is both scientifically validated and community-confirmed. Cycling rationale (receptor desensitization) is mechanistically plausible but not formally studied at community doses.
GHRP-6 Dosage Guide
Your first GHRP-6 injection will probably teach you something about hunger you didn't know before. The appetite hit comes fast, usually within 20 minutes, and it's more intense than most people expect. Plan a meal.
Reconstitution math for the standard 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg per mL, or 25 mcg per unit on a U-100 insulin syringe. So 100 mcg equals 4 units. 200 mcg equals 8 units. 300 mcg equals 12 units.
The thing most beginners miss is the empty stomach requirement. Food within 30 minutes before or after injection substantially blunts the GH pulse. If you eat too close to your dose, you're wasting peptide. Time your injection 30 minutes before a planned meal so the hunger window works in your favor.
Store reconstituted vials refrigerated at 2 to 8 degrees Celsius. Use within four weeks. If you see particulates, color changes, or smell anything off after reconstitution, discard the vial.
Continuous GHS-R1a agonism by GHRP-6 leads to receptor downregulation and reduced pituitary sensitivity over time. This is the primary documented mechanism driving cycling protocols. Community reports consistent with mechanistic expectation: hunger response and GH-pulse symptoms typically diminish after 8–12 continuous weeks. A 4–8 week off period allows GHS-R1a density to recover. Antibody formation is theoretically possible with any exogenous peptide but has not been specifically reported as a clinical concern with GHRP-6 at community doses.
- Reduced or absent hunger response post-injection (primary indicator)
- Blunted tingling/flushing GH-pulse effects
- Stalling sleep quality improvements
- Plateaued or declining IGF-1 levels mid-cycle
Or use the universal Peptide Calculator for any peptide.
GHRP-6 Protocols by Goal
Expected: Moderate GH/IGF-1 elevation; pronounced appetite increase; improved sleep depth; visible recovery improvement by week 6
Monitor: Check fasting glucose at baseline and week 6. Check IGF-1 at baseline and week 8.
How to Use GHRP-6
- 1Reconstitute a 5 mg vial with 2 mL bacteriostatic water
Aim the stream against the glass wall, not directly onto the powder. Swirl gently until dissolved. This gives you 2,500 mcg per mL.
- 2Step 2
Draw your dose using a U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle). For 100 mcg, draw to the 4-unit mark. For 200 mcg, draw to the 8-unit mark. For 300 mcg, draw to the 12-unit mark.
- 3Pinch a fold of skin on your abdomen or outer thigh
Insert the needle at a 45-degree angle into the subcutaneous fat layer. Inject slowly. Release the skin fold and withdraw.
- 4Step 4
Rotate injection sites with each dose to prevent lipodystrophy. Abdomen and outer thighs are the most common rotation areas.
- 5Timing matters
Inject on an empty stomach with no food 30 minutes before or after the injection. For pre-bed dosing, your last meal should be at least 30 minutes before the shot. For morning dosing, inject fasted and eat your first meal 30 minutes later.
- 6Step 6
If stacking with CJC-1295 No DAC (Mod GRF 1-29), you can draw both peptides into the same syringe and co-inject. Draw the CJC first, then the GHRP-6.
- 7Step 7
Refrigerate the reconstituted vial at 2 to 8 degrees Celsius after each use. Use within four weeks of reconstitution.
Alternative Routes
Reference dose
Inject into abdominal fat or outer thigh. Shorter distribution t½ (7.6 min) than elimination (2.5 h); GH pulse peak at 15–30 min. Rotate sites.
Requires 2–5× higher dose to match SC GH pulse; bioavailability estimates 5–15% intranasal vs. SC
Not common in community practice. Inconsistent absorption; requires nasal spray formulation. Not recommended for primary use.
Destroyed by GI proteases: negligible systemic absorption at standard doses
One 1995 study (PMID 7581965) showed modest GH response to oral GHRP-6 in children at very high doses (300 mcg/kg), not applicable to adult performance dosing. Oral route is not used in practice.
PK study (PMID 23099431) used IV for characterization; SC is standard clinical and community practice
IV was used in pharmacokinetic characterization studies only. Not a practical route for performance use.
GHRP-6 Stacking Protocols
Works With
Gold-standard GHRH pairing. Acts on the GHRH receptor independently of GHS-R1a; community reports describe a larger GH pulse than either alone. Co-inject in same syringe on empty stomach.
100 mcg CJC-1295 No DAC + 100–200 mcg GHRP-6, 2–3×/day
GHRH alternative to CJC-1295 No DAC. Shorter half-life (~12 min) but the same GHRH receptor pairing with GHRP-6. Some users prefer for milder, more physiologic GH pulse.
100–200 mcg sermorelin + 100 mcg GHRP-6, 1–2×/day pre-bed
Long-acting GHRH (half-life ~6–8 days). Provides sustained background GHRH elevation while GHRP-6 generates pulsatile GH spikes. Less pulsatile than No DAC pairing: more blunted but convenient.
1–2 mg CJC-1295 DAC 2×/week + 100–200 mcg GHRP-6 2–3×/day
Avoid
Competes for the same GHS-R1a receptor. Co-administration provides no added GH benefit: one GHRP displaces the other. Choose one GHRP; stack it with a GHRH instead.
Same GHS-R1a receptor competition: no added benefit from combining two GHRPs. If switching GHRPs mid-cycle for receptor variety, use sequentially, not simultaneously.
GHS-R1a competitor. Combining adds nothing and may increase cortisol/prolactin burden without added GH benefit.
Directly antagonize GH release at the pituitary: will negate GHRP-6 GH-stimulating effect entirely.
Do not combineEstimated Cost
Pricing updated 2026-04-09
GHRP-6 Side Effects
The most serious concern with GHRP-6 is its effect on blood glucose regulation. Growth hormone directly opposes insulin action, and GHRP-6 compounds this problem by driving appetite-fueled caloric surpluses that can push fasting glucose upward. Anyone with uncontrolled diabetes, insulin resistance, or prediabetes should treat this as a hard contraindication. Fasting glucose monitoring every four weeks during a cycle isn't optional at this dosing level.
Cortisol elevation is the second concern worth weighing carefully. GHRP-6 mildly raises ACTH and cortisol. Frieboes and colleagues saw both rise after four 50 mcg IV doses at night in healthy men [6]. Their 1999 follow-up found oral and intranasal GHRP-6 left cortisol unchanged [2]. At 100 mcg once daily, this is generally subclinical. Long-term cortisol data for GHRP-6 are lacking. In adults on hexarelin, a related GHRP, 16 weeks of twice-daily injections lowered the cortisol response [8]. At 200 to 300 mcg three times daily, watch for slower recovery, poorer sleep or stalled fat loss. Users running aggressive protocols should check morning cortisol at week four.
Prolactin elevation also occurs, more so than with ipamorelin. At aggressive doses, some users report symptoms consistent with raised prolactin. Baseline and week-four prolactin checks are warranted if dosing exceeds 200 mcg per injection.
Published side effects from the pharmacokinetic literature include tingling, facial flushing, dizziness, and transient warmth, all of which represent normal GH-pulse effects and typically resolve within 30 to 60 minutes. Community reports confirm these; they're predictable and dose-dependent.
Water retention is common at higher doses (200 to 300 mcg range). Users report two to four pounds of water weight during peak dosing weeks. This resolves within one to two weeks of dose reduction or cessation.
The appetite effect deserves its own warning. At 300 mcg, hunger becomes genuinely difficult to manage. This is a ghrelin mimetic doing exactly what ghrelin does. Users attempting to use GHRP-6 during a caloric deficit generally abandon the attempt; this peptide is a bulking tool.
Injection site reactions (redness, mild irritation) are possible with any subcutaneous peptide.
Pregnancy and breastfeeding are absolute contraindications. No human safety data exists for these populations.
Common Issues & Solutions
Hunger too intense to manage: Reduce to 50–75 mcg per injection, or restrict GHRP-6 use to pre-bed only. Hunger onset is ~20 min post-injection and peaks at ~45–60 min. Plan a high-calorie meal to follow; do not fast through the hunger window.
GH-pulse symptoms (tingling, dizziness, flushing) are severe: These are normal GH-pulse effects, typically resolving within 30–60 min. If persistent or severe, reduce dose by 50% and titrate up more slowly. Sitting during injection and for 15 min after reduces dizziness.
Diminishing response after 6–8 weeks (no hunger, no sleep improvement, no pump): GHS-R1a desensitization. Cycle off for 4–6 weeks. Adding a GHRH (CJC-1295 No DAC) may partially compensate but will not fully reverse desensitization: an off-cycle break is required.
Water retention is notable: At 300 mcg doses water retention can be significant. Reduce to 100–200 mcg, ensure adequate hydration and moderate sodium intake. Water retention typically resolves within 1–2 weeks of dose reduction or cessation.
No results despite following protocol: Verify (1) injections are on an empty stomach: food within 30 min substantially blunts GH pulse; (2) reconstitution math is correct (5 mg vial + 2 mL bac water = 4 units per 100 mcg on U-100 syringe); (3) peptide stored properly: refrigerated post-reconstitution, used within 4 weeks.
Ask AI about this page
Ask AI for a second opinion on GHRP-6 dosing and side effects
Contraindications
- Active malignancy or history of cancer (GH may promote tumor growth)
- Pregnancy or breastfeeding
- Uncontrolled diabetes or severe insulin resistance
- Active pituitary tumors or other intracranial neoplasia
- Known hypersensitivity to GHRP-6 or related peptides
- Severe obesity with untreated sleep apnea (GH may worsen)
Drug Interactions
- Insulin and sulfonylureas: GH opposes insulin action; monitor blood glucose closely for hypoglycemia risk
- Somatostatin analogs (octreotide, lanreotide): directly antagonize GHRP-6 GH-releasing mechanism
- Corticosteroids: combined cortisol elevation may impair glucose tolerance and recovery
- Dopamine agonists (cabergoline, bromocriptine): may blunt prolactin response but alter GH release dynamics
- Appetite suppressants (GLP-1 agonists, phentermine): pharmacological conflict with GHRP-6 orexigenic effects
- Competes for the same GHS-R1a receptor. Co-administration provides no added GH benefit: one GHRP displaces the other. Choose one GHRP; stack it with a GHRH instead.
Product Quality
GHRP-6 is in FDA's 503B Category 2 (since September 29, 2023) and is not on the 503A bulks list. All available supply is unregulated research-grade product. Purity varies; claims of ≥99% are not independently verified by FDA oversight. Self-assembly hydrogel research (PMID 41327290) highlights the precision required in formulation: conditions not guaranteed in generic research supply.
- Per-batch third-party HPLC/MS certificates of analysis (CoA) are the meaningful check: generic CoAs are not
- Verify 99%+ purity on the CoA matches your specific lot number
- Avoid vials with visible particulates, color, or odor after reconstitution
- Store lyophilized vials refrigerated (2–8°C); reconstituted vials refrigerated, use within 4 weeks
- GHRP-6 is in FDA's 503B Category 2 and is not on the 503A bulks list: check its legal status where you live
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| IGF-1 | Baseline, week 6–8, and end of cycle | 250–400 ng/mL (performance context); stay below 500 ng/mL |
| Fasting glucose | Baseline, then every 4 weeks during cycle | <100 mg/dL fasting; flag if >110 mg/dL |
| Morning cortisol | Baseline and week 4 (if using 200–300 mcg doses) | 6–23 mcg/dL (lab dependent) |
| Prolactin | Baseline and week 4 (if using 200–300 mcg doses or experiencing gynecomastia symptoms) | Males: 2–18 ng/mL; flag if >25 ng/mL |
Confirms GH axis is responding; ensures IGF-1 stays in a reasonable range (250–400 ng/mL target for most performance protocols)
GH elevation impairs insulin sensitivity; GHRP-6 appetite stimulation often drives caloric surplus: combined risk for glucose dysregulation
GHRP-6 mildly raises ACTH and cortisol after IV doses (PMID 7617137). Long-term data are lacking; in adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859).
GHRP-6 has mild prolactin-elevating effects vs. ipamorelin; clinically relevant at aggressive dosing
GHRP-6 Before and After
Initial GH pulses detectable within 15-30 minutes of injection. Intense hunger onset ~20 minutes post-dose. Possible tingling, dizziness, or flushing at injection site.
Appetite increase becomes predictable and pronounced. Sleep quality begins to improve, especially with evening dosing. Mild water retention may appear.
Cumulative GH elevation supports noticeable recovery improvements. Body composition shifts begin: increased lean mass, reduced fat. Hunger effects stabilize as users adapt meal timing around doses.
Full benefits realized: improved muscle fullness, faster recovery, deeper sleep. Cortisol and prolactin elevations remain mild and transient at standard doses. Consider cycling off after 8-12 weeks to prevent receptor desensitization.
What to Expect
Days 1 to 3: GH pulses show up fast. Community reports put the GH and hunger effects within 15 to 30 minutes of your first subcutaneous injection. Hunger kicks in around the 20-minute mark and it's not subtle. Tingling in the hands and feet, warm flushing across the face, and mild dizziness are all normal GH-pulse indicators. Most users notice deeper sleep on the very first night if dosing pre-bed.
Weeks 1 to 2: The hunger response locks into a predictable pattern. You'll know exactly when it hits and how long it lasts, which makes meal timing straightforward. Sleep quality improvement becomes consistent, especially with evening dosing. Expect one to two pounds of mild water retention. Energy and training capacity start trending upward.
Weeks 3 to 6: Body composition shifts become visible. Lean mass gains are noticeable; recovery between training sessions gets measurably faster. Strength gains vary by individual. Fat loss is generally blunted because the appetite effect drives caloric surpluses, this is a bulking tool by design. Some users report improved skin quality during this window. Water retention can peak at two to four pounds.
Weeks 6 to 12: Full benefits are on display. Muscle fullness, fast recovery, deep sleep. The hunger response may moderate slightly as your body adapts. By week 10 to 12, some users notice the GH-pulse sensations (tingling, flushing) starting to fade. That's GHS-R1a desensitization setting in, and it's the signal to cycle off for four to six weeks before your next run.
Detailed Timeline: Science vs Community
GH rises within 15–30 min of injection in community reports; the human PK study (PMID 23099431) measured plasma GHRP-6, not GH. Ghrelin-receptor agonism triggers orexigenic signal within ~20 min.
Immediate and intense hunger ~20–30 min post-injection. Tingling in hands/feet, warm flushing, mild dizziness: typical GH-pulse effects. Sleep feels deeper on night-time dose within first few nights.
Repeated pulsatile GH stimulation; early IGF-1 elevation emerging. Ghrelin signaling upregulates appetite consistently.
Hunger response becomes very predictable: users learn to time meals. Sleep quality improves noticeably, especially with pre-bed dosing. Mild water retention begins. Energy and training capacity trending up.
Sustained IGF-1 elevation supports anabolic signaling. GH-mediated lipolysis may begin competing with appetite-driven caloric surplus.
Visible lean mass gains. Recovery between sessions noticeably faster. Strength gains, though variable. Fat loss blunted by caloric surplus from appetite stimulation: this is a bulking tool, not a cut tool. Some users report skin quality improvements.
Maximal IGF-1 and body composition response achievable with this peptide class. GHS-R1a downregulation begins to emerge with continuous daily use beyond this window.
Full muscle fullness, improved body composition, deep sleep, fast recovery. Hunger response may slightly moderate as users adapt. Some report beginning of diminished GH-pulse sensation by week 10–12: cycling off recommended at this stage.
Pharmacokinetics
Source: Cabrales et al. Eur J Pharm Sci 2013 (PMID 23099431): IV bolus in nine healthy men; distribution t½ 7.6 min, elimination t½ 2.5 h
Pharmacokinetics: Active Dose Over Time
t½ = 7.6 min distribution, 2.5 h elimination (IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is GHRP-6 Legal?
GHRP-6 is not FDA-approved for any medical indication. It is classified as a research chemical in the United States. On September 29, 2023, FDA placed GHRP-6 in 503B Category 2, citing immunogenicity risk and possible effects on cortisol and blood glucose. It is not on the 503A bulks list (21 CFR 216.23), and FDA's 503A list (updated May 14, 2026) places it in Category 3. All GHRP-6 currently available is unregulated research-grade product.
For athletes, GHRP-6 is prohibited by the World Anti-Doping Agency (WADA) under the category of growth hormone secretagogues. It is banned both in-competition and out-of-competition.
Regulatory status varies by country. GHRP-6 is sold online labeled "for research purposes only."
This content is provided for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide or research compound.
Evidence grade: Phase 1 trial (Peptide Evidence Gap, October 2026)
Who Should Consider GHRP-6
- Adults seeking increased GH output for muscle growth
- Hard gainers needing appetite stimulation
- Athletes in mass-gaining or bulking phases
- Individuals stacking with GHRH peptides for amplified GH release
- Adults interested in improved sleep and recovery
Related Peptides
What Changed for GHRP-6
- Safety
Corrected Oct 17, 2026: the hexarelin cortisol study gives no ages in its abstract, so these pages say adults, not older adults, per Rahim 1999.
Before: In healthy older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859) After: In adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)
What this does not mean: The finding stands: 16 weeks of twice-daily hexarelin lowered the cortisol response and left the prolactin response unchanged. Only the description of the study group changed.
Also covers: GHRP-2, Hexarelin
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: GHRP-6's prolactin rise is no longer ranked below hexarelin's; the human head-to-head tests used GHRP-2, per Arvat 1997.
Before: Prolactin elevation also occurs, more so than with ipamorelin but less than hexarelin After: Prolactin elevation also occurs, more so than with ipamorelin
What this does not mean: GHRP-6 still raises prolactin, ACTH and cortisol. Human head-to-head data against hexarelin on these hormones are lacking.
Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: oral and intranasal GHRP-6 left cortisol unchanged, per Frieboes 1999; the IV rise the page credited to it is from 1995.
Before: GHRP-6 mildly raises ACTH and cortisol, confirmed by Frieboes and colleagues in their neuroendocrine study (PMID 10336729) After: IV GHRP-6 raised ACTH and cortisol (PMID 7617137); oral and intranasal GHRP-6 left cortisol unchanged (PMID 10336729)
What this does not mean: GHRP-6 still raises ACTH and cortisol after IV doses (PMID 7617137). This moves a citation; it is not a new safety finding.
Source: J Neuroendocrinol 1999, Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration (Frieboes et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 16, 2026: GHRP-6's cumulative cortisol load claim is gone; 16 weeks of hexarelin in older adults lowered the cortisol response, per Rahim 1999.
Before: At 200 to 300 mcg three times daily, the cumulative cortisol load becomes meaningful enough to potentially impair recovery, sleep quality, and fat metabolism After: Long-term cortisol data for GHRP-6 are lacking; in older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)
What this does not mean: GHRP-6 still raises ACTH and cortisol after IV doses. Long-term cortisol data for GHRP-6 itself are lacking, and the week-four morning cortisol check on aggressive protocols stays.
Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202614 Citations
References
- [1]Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers (Eur J Pharm Sci 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Effects of GHRP-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration (Frieboes et al., J Neuroendocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol turnover in human pituitary somatotroph cells (J Mol Endocrinol 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects (Berlanga-Acosta et al., Clin Med Insights Cardiol 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds (Plast Surg Int 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man (Frieboes et al., Neuroendocrinology 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone (Bowers et al., J Clin Endocrinol Metab 1990) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al., Clin Endocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]GH releasing peptides: structure and kinetics (Bowers, J Pediatr Endocrinol 1993) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [10]Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation (Zhao et al., J Nanobiotechnology 2025) (opens in a new tab)PubMed 41327290PubMed
- Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature (Eur J Endocrinol 1995) (opens in a new tab)PubMed 7581965PubMed
- Their 2017 (PMC11169835) (opens in a new tab)PubMed
- Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al., Peptides 1997) (opens in a new tab)PubMed 9285939PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is GHRP-6?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 200-400. Community mentions on Reddit: ~200-400 threads (r/Peptides, r/PEDs). Open r/Peptides (opens in a new tab).
320 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.